ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ezetimibe

Also written as “ezetimibe”, “ezetimibe (+) simvastatin” and “MK0653, ezetimibe”.

Its studies are mostly in Hypercholesterolemia · Hypertension · Hyperlipidemias · Lipid Metabolism, Inborn Errors · Atherosclerosis, led by 16 companies.

Drug pageEzetimibe: every studyMany companies study it; this page follows only the 97 they lead. All 208 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 7, 200597 company-led studies, 3 open or runningNext primary completion: Jun 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon710 open or runningphase 4since Sep 7, 2005Sep 23, 2004none ahead
Daiichi Sankyoits history only61 open or runningphase 4since Sep 9, 2005Sep 9, 2005Jun 1, 2028phase 3 · NCT07474649
Yuhanits history only40 open or runningphase 4since Jul 12, 2017Jul 12, 2017none ahead
IlDong Pharmaceuticalits history only20 open or runningphase 3since Sep 25, 2014Sep 25, 2014none ahead
JW Pharmaceuticalits history only21 open or runningphase 4since Feb 18, 2026Oct 6, 2020none ahead
Novartisits history only20 open or runningphase 4since Oct 10, 2006Sep 12, 2005none ahead
Celltrionits history only10 open or runningphase 3since Apr 27, 2026Apr 27, 2026none ahead
Daewon Pharmaceuticalits history only10 open or runningphase 3since Jul 24, 2023Jul 24, 2023none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Mar 22, 2012Mar 22, 2012none ahead
Hanlim Pharm.its history only10 open or runningphase 3since Dec 2, 2020Dec 2, 2020none ahead

Also a collaborator on its studies: Pharma Medica Research, Regeneron Pharmaceuticals, Merck Frosst Canada, Linical Korea and Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Organon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 24 studies since Aug 9, 2005.

  1. Mar 31, 20086 phase 4 studiesNCT00652444, NCT00652327, NCT00651963 and 3 more
  2. Mar 31, 20086 phase 3 studiesNCT00652301, NCT00651560, NCT00651404 and 3 more
  3. Apr 1, 20082 phase 3 studies in HypercholesterolemiaNCT00654095, NCT00653523
  4. Apr 1, 20085 phase 4 studiesNCT00653835, NCT00653796, NCT00652847 and 2 more
  5. Apr 1, 2008Phase 1 study in CholesterolNCT00653276 · 13 enrolled
  6. Mar 12, 20092 phase 3 studiesNCT00862251, NCT00867165
  7. Mar 26, 2009Phase 4 study in Primary HypercholesterolemiaNCT00871351 · 125 enrolled
  8. Jun 29, 2010Phase 3 study in HypercholesterolemiaNCT01154036 · 1,547 enrolled
  9. Jun 8, 20112 phase 3 studies in HypercholesterolemiaNCT01370603, NCT01370590
  10. Jun 1, 2012Phase 4 study in HypercholesterolemiaNCT01611883 · 152 enrolled
  11. May 29, 2015Phase 3 study in HypercholesterolemiaNCT02460159 · 135 enrolled
  12. Sep 14, 2015Phase 3 study in HypercholesterolemiaNCT02550288 · 309 enrolled
  13. Apr 13, 20162 phase 3 studies in HypercholesterolemiaNCT02741245, NCT02748057
  14. Mar 6, 20195 phase 3 studiesNCT03884452, NCT03867110, NCT03882996 and 2 more

TargetBeta

NPC1L1 →read by rule
“Niemann-Pick C1-like protein 1 inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 71 Organon leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT03882996Hypercholesterolemia3CompletedFeb 4, 2003432
NCT03882905Primary Hypercholesterolemia3CompletedJul 27, 2001769
NCT03882892Hypercholesterolemia3CompletedAug 8, 2002400
NCT03884452Hyperlipoproteinemia Type II3CompletedMay 24, 200150
NCT03867110Hypercholesterolemia3CompletedJul 27, 2001628
NCT02748057Hypercholesterolemia3CompletedDec 11, 2017135
NCT02741245Hypercholesterolemia3CompletedJan 18, 2017321
NCT02550288Hypercholesterolemia3CompletedMay 30, 2016309
NCT02460159Hypercholesterolemia3CompletedDec 22, 2016135
NCT01611883Hypercholesterolemia4CompletedJan 16, 2014152
NCT01370603Hypercholesterolemia3CompletedMay 2012328
NCT01370590Hypercholesterolemia3CompletedApr 2012406
NCT01154036Hypercholesterolemia3CompletedSep 20121,547
NCT00871351Primary Hypercholesterolemia4CompletedMay 1, 2010125
NCT00867165Primary Hypercholesterolemia3CompletedApr 13, 2012138
NCT00862251Cardiovascular Diseases3CompletedMar 2011808
NCT00654628Hypercholesterolemia4CompletedJul 1, 2009173
NCT00654095Hypercholesterolemia3CompletedJun 1, 2009146
NCT00653835Hypercholesterolemia4CompletedAug 1, 2004153
NCT00653796Hypercholesterolemia4CompletedAug 1, 2004148
NCT00653523Hypercholesterolemia3CompletedJun 1, 2009151
NCT00653276Cholesterol1CompletedJan 200413
NCT00652847Hypercholesterolemia4CompletedMay 20071,140
NCT00652717Cardiovascular Diseases4CompletedFeb 15, 2005280
NCT00653913Hypercholesterolemia1CompletedSep 200418
NCT00652444Hypercholesterolemia4CompletedAug 2004120
NCT00652327Hypercholesterolemia4CompletedJul 200783
NCT00652301Cholesterol3CompletedApr 200440
NCT00651963Lipid Metabolism Disorders4CompletedMar 200580
NCT00651560Hyperlipidemias3CompletedDec 23, 2005167
NCT00651404Hypercholesterolemia3CompletedDec 2004137
NCT00651391Hypercholesterolemia3TerminatedSep 1, 200428
NCT00651274Atherosclerosis4CompletedAug 1, 2004144
NCT00651144Hypercholesterolemia1CompletedMay 200340
NCT00651014Hypercholesterolemia4TerminatedJun 200682
NCT00650819Hypercholesterolemia3CompletedFeb 1, 2005240
NCT00650689Hypercholesterolemia3CompletedDec 2004122
NCT00650663Hypercholesterolemia4CompletedSep 1, 2004247
NCT00552097Atherosclerosis3CompletedApr 25, 2006720
NCT00535405Hypercholesterolemia3CompletedMar 20091,289
NCT00496730Hypercholesterolemia3CompletedAug 2008256
NCT00479713Hypercholesterolemia3CompletedMar 1, 2008618
NCT00462748Hypercholesterolemia3CompletedJun 2008786
NCT00457275Hypercholesterolemia3CompletedNov 2005440
NCT00442897Hypercholesterolemia4CompletedOct 2008229
NCT00423579Hypercholesterolemia4CompletedMar 1, 2008120
NCT00423488Hypercholesterolemia3CompletedFeb 16, 200793
NCT00418834Hypercholesterolemia3CompletedOct 20081,053
NCT00413972Hypercholesterolemia3CompletedNov 2006392
NCT00409773Hypercholesterolemia3CompletedJul 20081,143
NCT00395473Hypercholesterolemia3CompletedNov 2005141
NCT00319449Hypercholesterolemia4CompletedOct 200622
NCT00276484Hypercholesterolemia3CompletedFeb 2008579
NCT00276458Hypercholesterolemia3CompletedJan 2008196
NCT00271817Hypercholesterolemia3CompletedFeb 20081,220
NCT00202904Hypercholesterolemia4CompletedOct 200681
NCT00166530Atherosclerosis4CompletedFeb 2007367
NCT00166504Hypercholesterolemia4CompletedOct 2007203
NCT00157924Hypercholesterolemia4CompletedSep 2007190
NCT00129402Hypercholesterolemia3CompletedJun 2007248

How it is read

Names in the registry

  • “Ezetimibe”, 31 entries
  • “ezetimibe”, 11 entries
  • “ezetimibe (+) simvastatin”, 10 entries
  • “MK0653, ezetimibe”, 7 entries
  • “CKD-828, D097, D337”, 6 entries

Codes read as this program: MK0653.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.